Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
A Duet of Bone and the Immune System
Examining emerging perspectives in osteoimmunology
Integrating Immunology and Biologics into Clinical Practice
With the rapid expansion of new classes of medications, clinical practice has changed dramatically, and rheumatology health professionals must have a fundamental knowledge of immunology and the mechanisms of action of the biologic agents that have emerged with this expansion. Familiarity with the predrug screening recommended for biologic agents and the appropriate safety and disease monitoring necessary when a person uses these products is essential for the best patient outcomes. Additionally, being able to obtain drug plan authorization for use of biologics and being able to educate patients and their families or support team members about the financial considerations of these drugs helps to ensure best rheumatology practice.
European Beacon for Rheumatology
Josef S. Smolen, MD, led the way for outcomes measures and a scientifically based training program